What is the best approach to target KRAS: PROTAC or DAC?
- Introducing Polymed’s optimized development approach to create best-in-class PROTACs and DACs
- Development of Polymed’s PROTAC targeting KRAS G12D optimized for potency, selectivity, bioavailability, and ADME properties
- Creation of a KRAS G12D degrader antibody conjugate: the next frontier of KRAS targeted therapies